Resverlogix Corp. is a late-stage clinical biotechnology company focused on improving the lives of patients with chronic illnesses. The company develops apabetalone, a drug that regulates gene expression by inhibiting bromodomain and extraterminal domain (BET) proteins, targeting multiple biological processes associated with diseases such as cardiovascular disease. Resverlogix completed a Phase 3 clinical trial, BETonMACE, for apabetalone in high-risk cardiovascular disease patients with type 2 diabetes mellitus and low levels of high-density lipoprotein, aiming to enhance treatment outcomes alongside existing therapies.
- Website
- www.resverlogix.com
- Issuer profile
- All listings